Aim: To determine if photodynamic therapy (PDT) outcomes are related to lesion size in patients with subfoveal predominantly classic choroidal neovascularisat ion (CNV) secondary to age related macular degeneration (AMD). Methods: Accordin g to greatest linear dimension (GLD) of the entire lesion determined with fluore scein angiography (FA) patients were divided into two groups. In the first group GLD was < 3000 μm and in the second one GLD was 3000-5000 μm. All eyes were treated with standard PDT with the verteporfin protocol. The primary outcome was the proportion of eyes in both groups that did not show significant leakage in FA at the end of follow up. Secondary outcomes were changes in GLD and in best corrected visual acuity (BCVA). Resul ts: 64 patients (mean (SD) age, 76.7 (7.7) years; range 58-95 years) were recru ited to participate in the study. All participants in the study completed the fo llow up time (mean 16.6 months). 24 patients (75%) in the group of smaller lesi ons (n=32) compared with 15 patients (46.8%) in the group of larger lesions (n= 32) did not show significant leakage in FA at the end of follow up (p=0.02). A G LD increase >1000 μm was recorded in nine eyes (28.1%) in the group of smaller lesions and in 16 eyes (50%) in the group of larger lesions (p=0.07). 22 eyes (68.7%) in the group of smaller lesions compared with 19 eyes (59.3%) in the g roup of larger lesions lost less than three lines of vision (p=0.06). Relevant s ide effects related to verteporfin therapy were not recorded, except for four pa tients (6.2%) with infusion related back pain. Conclusions: These results sugge st that lesion size at baseline may be a prognosis factor in PDT in patients wit h subfoveal predominantly classic CNV secondary to AMD. There are no relevant si de effects or safety concerns derived from verteporfin therapy. Aim: To determine if photodynamic therapy (PDT) outcomes are related to lesion size in patients with subfoveal predominantly classic choroidal neovascularisation (CNV) secondary to age related macular degeneration (AMD). Methods: Accordin g to greatest linear dimension (GLD) of The entire lesion determined with fluore scein angiography (FA) patients were divided into two groups. In the first group GLD was <3000 μm and in the second one GLD was 3000-5000 μm. All eyes were treated with standard PDT with the verteporfin protocol Secondary outcome were changes in GLD and in best corrected visual acuity (BCVA). Resul ts: 64 patients (mean (SD) age, 76.7 (7.7) years; range 58-95 years) were recruited to participate in the study. All participants in the study completed the fo llow up time (mean 16.6 months). 24 patients (75%) in the group of lesser lesi on (n = 32) did not show significant leakage in FA at the end of follow up (p = 0.02). AG LD increase> 1000 μm (46.8%) in the group of larger lesions was recorded in nine eyes (28.1%) in the group of smaller lesions and in 16 eyes (50%) in the group of larger lesions (p = 0.07). 22 eyes (68.7%) in the group smaller lesions compared with 19 (60%) with the infusion related back (59.3%) in the g roup of larger lesions lost less than three lines of vision (p = 0.06). pain. Conclusions: These results sugge st that lesion size at baseline may be a prognosis factor in PDT in patients wit h subfoveal predominantly classic CNV secondary to AMD. There are no relevant si de effects or safety concerns derived from verteporfin therapy.